山东大学学报 (医学版) ›› 2022, Vol. 60 ›› Issue (1): 118-120.doi: 10.6040/j.issn.1671-7554.0.2021.1080
• 病例报道 • 上一篇
陈峰1,高沛1,朱可嘉2,丁森泰1,2
中图分类号:
| [1] Stenehjem D, Tran D, Nkrumah M, et al. PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer[J]. Onco Targets Ther,2018, 2018(11):5973-5989. [2] Zavalishina LE, Andreeva YY, Olyushina EM, et al. Immunohistochemical study of the MSI phenotype of urothelial bladder cancer[J]. Arkh Patol, 2020, 82(1):5-14. [3] Fraune C, Simon R, Hube-Magg C, et al. MMR deficiency in urothelial carcinoma of the bladder presents with temporal and spatial homogeneity throughout the tumor mass[J]. Urol Oncol, 2020, 38(5): 488-495. [4] Eckstein M, Hartmann A, Strissel P, et al. Comparative analysis of tumour mutational burden(TMB)prediction methods and its association with determinants of the tumour immune microenvironment of urothelial bladder cancer(UBC)[J]. Ann Oncol, 2019, 30(5): 376-377. [5] Tang X, Qian WL, Yan WF, et al. Radiomic assessment as a method for predicting tumor mutation burden(TMB)of bladder cancer patients: a feasibility study [J]. BMC Cancer, 2021, 21(1): 823-823. [6] Albandar HJ, Fuqua J, Albandar JM, et al. Immune-related adverse events(irAE)in cancer immune checkpoint inhibitors(ICI)and survival outcomes correlation: to rechallenge or not? [J]. Cancers,2021, 13(5): 989-991. [7] Kenichi C, Toshiaki U, Keisuke A, et al. PD1-1-5 Frequency of immune-related adverse events of immune-checkpoint inhibitors for non-small cell lung cancer in our single institution[J]. Ann Oncol, 2021, 32(4):325-325. [8] Rubino R, Marini A, Roviello G, et al. Endocrine-related adverse events in a large series of cancer patients treated with anti-PD1 therapy[J]. Endocr, 2021,74(1):172-179. [9] Lui DTW, Lee CH, Tang V, et al. Thyroid immune-related adverse events in cancer patients treated with anti-PD1/Anti-CTLA4 immune-checkpoint inhibitor combination: clinical course and outcomes[J]. Endocr Pract, 2021, 27(9): 886-893. [10] Kosuke N, Yosuke Y, Kenji K, et al. Primary lymphoepithelioma-like carcinoma of the esophagus with metastatic lymph node and gastric cancer[J]. Clin J Gastroenterol, 2021, 14(5): 1329-1336. [11] 李凯, 杨潇, 李鹏超, 等. 膀胱淋巴上皮瘤样癌1例报告[J].实用老年医学, 2021, 35(6): 636-637. [12] 范大铬, 黄海建, 吴春林. 膀胱淋巴上皮瘤样癌2例并文献复习[J].临床与实验病理学杂志, 2017, 33(10): 1153-1155. [13] Amin MB, Ro JY, Lee KM, et al. Lymphoepithelioma-like carcinoma of the urinary bladder[J]. Am J Surg Pathol, 1994, 18(5): 466-473. [14] Serrano GB, Funez FA, Lopez RG, et al. Bladder lymphoepithelioma-like carcinoma: bibliographic review and case report[J]. Arch Esp Urol, 2008, 61(6): 723-729. [15] Fang W, Hong S, Chen N, et al. PD-L1 is remarkably over-expressed in EBV-associated pulmonary lymphoepithelioma-like carcinoma and related to poor disease-free survival[J]. Oncotarget, 2015, 6(32): 33019-33032. [16] Alessandro R, Dalia RA, Giovanni B. PD-L1, TMB, MSI, and other predictors of response to immune checkpoint inhibitors in biliary tract cancer[J]. Cancers, 2021, 13(3): 558-558. [17] Rodrigues DN, Rescigno P, Liu D, et al. Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer[J]. J Clin Invest, 2018, 128(10): 4441-4453. [18] 辇伟奇, 聂勇战, 应建明,等. 肿瘤突变负荷检测及临床应用中国专家共识(2020年版)[J].中国癌症防治杂志, 2020, 12(5): 485-494. [19] Zhou F, Huang Y, Cai WJ, et al. The genomic and immunologic profiles of pure pulmonary sarcomatoid carcinoma in Chinese patients[J]. Lung Cance, 2021, 15(3): 66-72. [20] Nalin L, Hong CS, Bindra RS. The role of mismatch repair in glioblastoma multiforme treatment response and resistance[J]. Neurosurg Clin N Am, 2021, 32(2): 171-180. [21] Machado-Neves R, Bernardo T, Elsa F, et al. Penile lymphoepithelioma-like carcinoma: a rare case with PD-L1 expression [J]. Int J Surg Pathol, 2021, 29(6): 690-692. |
| [1] | 李波波 李道堂 刘曙光 王兴武. 食管癌患者血清中DKK-1的表达[J]. 山东大学学报(医学版), 2209, 47(6): 58-61. |
| [2] | 王欣，邢春燕，杨艳平. 血清磷酸丙酮酸水合酶检测对诊断侵袭性白念珠菌感染的临床价值[J]. 山东大学学报(医学版), 2209, 47(6): 92-94. |
| [3] | 徐平 于国放 李霞. 不同类型甲状腺上动脉PSV对Graves病与桥本氏甲状腺炎鉴别诊断的价值[J]. 山东大学学报(医学版), 2209, 47(6): 62-64. |
| [4] | 王传新. 肿瘤液体活检[J]. 山东大学学报 (医学版), 2021, 59(9): 64-71. |
| [5] | 许长娟,梁子婷,曾荣,黄思源,王静,董亮. 结节性硬化症合并肺淋巴管肌瘤病1例[J]. 山东大学学报 (医学版), 2021, 59(8): 119-121. |
| [6] | 陈刚,张焰平,叶乐平,付冲,周春燕,张世栋. 造影增强超声内镜联合超声内镜引导下细针抽吸术对胰腺占位的诊断价值[J]. 山东大学学报 (医学版), 2021, 59(7): 68-73. |
| [7] | 邢小平. 原发性骨质疏松症诊治思考[J]. 山东大学学报 (医学版), 2021, 59(6): 1-4. |
| [8] | 米琦,史爽,李娟,李培龙,杜鲁涛,王传新. 膀胱癌circRNAs介导的ceRNA网络及预后评估模型的构建[J]. 山东大学学报 (医学版), 2021, 59(6): 94-102. |
| [9] | 高金梅,张向莲,刘铁菊. 血浆D-二聚体与109例膀胱癌中发生31例转移的关联性分析[J]. 山东大学学报 (医学版), 2021, 59(3): 98-102. |
| [10] | 潘虹江,王焕昇,裴发军,杨明山. 孤立性膀胱子宫内膜异位症1例[J]. 山东大学学报 (医学版), 2021, 59(2): 122-124. |
| [11] | 陆梓文,李光兵,郑顺贞,杨洋,刘军. 肝脏胆管腺纤维瘤1例报道[J]. 山东大学学报 (医学版), 2021, 59(11): 120-122. |
| [12] | 王国云,王凯,袁明,陈子江. 子宫内膜异位症立体化管理体系(山东方案)[J]. 山东大学学报 (医学版), 2021, 59(10): 1-16. |
| [13] | 杜甜甜,李娟,赵颖慧,段伟丽,王景,王允山,杜鲁涛,王传新. 长链非编码RNA LINC02474在结直肠癌中的表达特征及对细胞增殖的影响[J]. 山东大学学报 (医学版), 2021, 59(10): 57-67. |
| [14] | 李晗,曹学峰,张兴元,成雨,孔令群. 原发性乙状结肠鳞癌1例[J]. 山东大学学报 (医学版), 2021, 59(10): 120-122. |
| [15] | 柴佳威,朱坤兵,李亚琼,王甜甜. 隐匿性甲状腺癌:1例病例报道和文献回顾[J]. 山东大学学报 (医学版), 2021, 59(1): 83-87. |
|
||
